PharmaShots | Incisive News in 3 Shots

Subscribe Now

eyepoint pharmaceuticals

EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Dege...

October 25, 2024

EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy

May 6, 2024

EyePoint Pharmaceuticals Reports Results for EYP-1901 in P-II Trial for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports Results for EYP-1901 in P-II Trial for the Treatment of Wet Age-Related Macular Degeneration

February 5, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us